Checkmate Pharmaceuticals Inc
CMPI
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-39,478,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.84 |
| Beta | 0 |
| Outstanding Shares | 21,630,600 |
Return
| Return on Equity | -114.84% |
|---|---|
| Return on Assets | -94.35% |
| Return on Invested Capital | -114.77% |
Valuation & Multiples
| P/E Ratio | -3.7 |
|---|---|
| PEG | -29.72 |
| Price to Sales | - |
| Price to Book Ratio | 5.25 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.63 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Checkmate Pharmaceuticals Inc
25 employeesCheckmate Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops novel approaches for cancer immunotherapy such as immuno-oncology. Checkmate Pharmaceuticals serves patients worldwide.